Cogent Biosciences Advances Bezuclastinib Launch, Moves Closer to FDA Approval
Published: 13 Mar 2026
Author: Precedence Research
Cogent Biosciences is moving forward with its targeted therapy, Bezuclastinib, toward a potential commercial launch, making an important development in systemic mastocystosis treatment. The biotechnology company recently highlighted clinical-stage progress for the drug candidate and is currently awaiting regulatory approval from the U.S. Food and Drug Administration (FDA).
During an update earlier this year, the company emphasized that it has entered 2026 with substantial momentum reinforced by several regulatory and clinical catalysts. Cogent’s position in the rare disease therapeutics market, particularly for disorders driven by KIT mutations, is expected to strengthen with these developments.
Bezuclastinib is a potent and selective inhibitor designed to target the KIT D816V mutation. The therapy aims to reduce abnormal mast-cell activity, which is responsible for the severe symptoms experienced by patients with systemic mastocytosis and gastrointestinal stromal tumors (GIST). If approved, the therapy could enable an important new alternative for patients suffering from this rare hematologic disorder.
The drug’s clinical progress is supported by reassuring clinical data. Results from the SUMMIT clinical trial of bezuclastinib in patients with non-advanced systemic mastocytosis demonstrated notable clinical benefit across all symptom domains. The trial findings, which highlighted the therapy’s potential to improve disease management and patients' quality of life, generated strong interest in the medical field.
According to Precedence Research, the Systemic Mastocytosis Treatment Market size accounted for USD 562.18 million in 2025 and is predicted to increase from USD 612.55 million in 2026 to approximately USD 1,326.01 billion by 2035, expanding at a CAGR of 8.96% from 2026 to 2035 as demand grows for faster, scalable Systemic Mastocytosis Treatment.
Six abstracts related to the SUMMIT trial of bezuclastinib have been accepted for presentation at the 2026 annual meeting of the American Academy of Allergy, Asthma & Immunology (AAAAI). These presentations are expected to provide deeper insights into the clinical benefits of bezuclastinib and its potential role in treating mast-cell-driven disorders.
Cogent Biosciences appears financially well-positioned to enable the continued development and potential commercialization of the therapy. The company exited 2025 with approximately $900.8 million in cash equivalents and marketable securities, while also repaying $54.8 million in long-term debt during the fourth quarter.
As the company pushes its pipeline forward, research and development investments have also increased. Research and development expenses increased to $75.6 million in the fourth quarter of 2025 from $62 million in the fourth quarter of 2024. On a full-year basis, R&D expense reached $269.8 million, up from $232.7 million in 2024, reflecting Cogent’s ongoing commitment to advancing precision therapies for genetically defined diseases.
Despite these investments, net loss widened to $102.5 million in the fourth quarter and to $328.9 million for the full year 2025, compared to $67.9 million and $255.9 million for the fourth quarter and full year 2024, respectively. With regulatory approval, bezuclastinib could soon play a key role in expanding treatment alternatives for systemic mastocytosis and related conditions.